Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Levy

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Medical Care|September 1, 1979
Primary care. Patterns of use of pediatric medical facilitiesJ C Levy, R A Bonanno, C G Schwartz, et al.
Diabetes|January 1, 1993
Normal proinsulin responses to glucose in mild type II subjects with subnormal insulin responseJ C Levy, P M Clark, C N Hales, et al.
Diabetes|January 1, 1995
Type II diabetes: clinical aspects of molecular biological studiesR C Turner, A T Hattersley, J T Shaw, et al.
European Journal of Pharmacology|September 15, 1993
Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissuesF J Kidd, J C Levy, M Nielsen, et al.
Diabetologia|July 11, 2002
Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic siblingO M Herlihy, B A Barrow, P J Grant, et al.
Metabolism: Clinical and Experimental|September 1, 1991
Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetesA S Rudenski, D R Matthews, J C Levy, et al.
Pediatric Clinics of North America|May 1, 1974
An integrated system for health supervisionJ C Levy, R M Strong, C Browne, et al.
European Journal of Pharmacology|January 28, 1992
The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous systemE Kidd, I Bouchelet de Vendegies, J C Levy, et al.
Diabetes|September 1, 1992
Elevated plasma concentrations of beta-cell tropin (ACTH22-39) in diet-treated type II diabetic patientsJ C Levy, J L Morton, M Davenport, et al.
Diabetes|October 6, 1997
Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapyJ Rachman, J C Levy, B A Barrow, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Medical Care|September 1, 1979
Primary care. Patterns of use of pediatric medical facilitiesJ C Levy, R A Bonanno, C G Schwartz, et al.
Diabetes|January 1, 1993
Normal proinsulin responses to glucose in mild type II subjects with subnormal insulin responseJ C Levy, P M Clark, C N Hales, et al.
Diabetes|January 1, 1995
Type II diabetes: clinical aspects of molecular biological studiesR C Turner, A T Hattersley, J T Shaw, et al.
European Journal of Pharmacology|September 15, 1993
Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissuesF J Kidd, J C Levy, M Nielsen, et al.
Diabetologia|July 11, 2002
Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic siblingO M Herlihy, B A Barrow, P J Grant, et al.
Metabolism: Clinical and Experimental|September 1, 1991
Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetesA S Rudenski, D R Matthews, J C Levy, et al.
Pediatric Clinics of North America|May 1, 1974
An integrated system for health supervisionJ C Levy, R M Strong, C Browne, et al.
European Journal of Pharmacology|January 28, 1992
The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous systemE Kidd, I Bouchelet de Vendegies, J C Levy, et al.
Diabetes|September 1, 1992
Elevated plasma concentrations of beta-cell tropin (ACTH22-39) in diet-treated type II diabetic patientsJ C Levy, J L Morton, M Davenport, et al.
Diabetes|October 6, 1997
Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapyJ Rachman, J C Levy, B A Barrow, et al.
Pageof 10